A randomized, double-blind, 6-week prospective pilot study on the efficacy and safety of dose escalation in non-remitters in comparison to those of the standard dose of escitalopram for major depressive disorder-Reference-Cited by-同舟云学术

A randomized, double-blind, 6-week prospective pilot study on the efficacy and safety of dose escalation in non-remitters in comparison to those of the standard dose of escitalopram for major depressive disorder

Published:2019-12 Issue: Volume:259 Page:91-97
ISSN:0165-0327
Container-title:Journal of Affective Disorders
language:en
Short-container-title:Journal of Affective Disorders

Author:

Kim Eun Young,Kim Se Hyun,Lee Hyun Jeong,Lee Nam Young,Kim Hye Young,Park C. Hyung Keun,Ahn Yong Min

Funder

Lundbeckfonden

Publisher

Elsevier BV

Subject

Psychiatry and Mental health,Clinical Psychology

Reference27 articles.

1. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review;Adli;Eur. Arch. Psychiatry Clin. Neurosci.,2005

2. Practice guideline for the treatment of patients with major depressive disorder (revision);Am. J. Psychiatry,2000

3. Evidence that the SSRI dose response in treating major depression should be reassessed: a meta-analysis;Baker;Depress. Anxiety,2003

4. QT prolongation, torsades de pointes, and psychotropic medications: a 5-year update;Beach;Psychosomatics,2018

5. Minimum effective dose for antidepressants–an obligatory requirement for antidepressant drug evaluation?;Benkert;Int. Clin. Psychopharmacol.,1996

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. “Sensing the Mind”: An Exploratory Study About Sensors Used in E-Health and M-Health Applications for Diagnosis of Mental Health Condition;Internet of Things;2021

2. An Exploratory Pilot Study with Plasma Protein Signatures Associated with Response of Patients with Depression to Antidepressant Treatment for 10 Weeks;Biomedicines;2020-10-28